Pasithea Therapeutics Corp. (KTTA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pasithea Therapeutics Corp. (KTTA) closed at USD 0.41 on 2026-10-15, a change of -43.4 % over the past year, with a market capitalization of USD 14.03M.

Pasithea Therapeutics Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pasithea Therapeutics Corp. key figures

Previous close

USD 0.41 (2026-10-15)

1-year change

-43.4 %

Market cap

USD 14.03M

Enterprise value

USD -31.63M

P/E ratio (trailing)

-0.26

P/E ratio (forward)

-0.91

EPS (trailing)

-1.59

EPS (forward)

-0.46

PEG ratio

n/a

Price to book

0.28

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.83

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pasithea Therapeutics Corp. and compare it with other stocks.